Broncho-Vaxom® (Capsules) Instructions for Use
ATC Code
L03AX (Other immunostimulants)
Clinical-Pharmacological Group
Immunostimulating drug of bacterial origin
Pharmacotherapeutic Group
MIBP
Pharmacological Action
Immunostimulating drug of bacterial origin. It induces an immune response in the mucosa of the digestive tract. The effect is particularly pronounced in the Peyer’s patches (PP) of the small intestine. Antigen-presenting cells (APC) in the PP are activated by the drug and subsequently stimulate cells responsible for specific immunity.
Administration of the drug leads to an increase in the number of circulating B-lymphocytes. Following stimulation of B-lymphocytes, an increase in the production of polyclonal antibodies is observed, particularly serum IgG and IgA secreted by the respiratory mucosa and saliva. These antibodies serve as the first line of defense against a wide range of infectious agents (viruses and bacteria).
The drug exerts a powerful stimulatory effect on most types of leukocytes, as evidenced by an increase in the number of myeloid and lymphoid lineage cells, as well as a selective increase in receptor expression on their surface.
Collectively, these data confirm that the drug initiates biological responses that enhance the body’s immune defense against infection.
Clinically, Broncho-Vaxom® adult reduces the frequency of acute respiratory tract infections, shortens their duration, decreases the likelihood of chronic bronchitis exacerbations, and increases the body’s resistance to respiratory system infections. This subsequently reduces the need for other medications, especially antibiotics.
Indications
Prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis.
Treatment of acute respiratory tract infections (as part of combination therapy).
ICD codes
| ICD-10 code | Indication |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J20 | Acute bronchitis |
| J31 | Chronic rhinitis, nasopharyngitis and pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| Z29.8 | Other specified prophylactic measures |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally. Use the dosage form appropriate for the patient’s age.
For prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis: Take one capsule daily on an empty stomach for 10 consecutive days per month. Continue this cycle for three consecutive months.
For treatment of acute respiratory tract infections as part of combination therapy: Take one capsule daily on an empty stomach until symptoms resolve, but for a minimum of 10 days.
For optimal absorption, take in the morning, at least 30 minutes before food or any other medication.
Swallow the capsule whole with a glass of water. Do not chew or crush.
If a dose is missed, take it as soon as remembered on the same day. Do not take a double dose to make up for a forgotten one.
Adverse Reactions
Gastrointestinal system Common – diarrhea, abdominal pain; Unknown – vomiting, nausea.
Nervous system Unknown – headache.
Respiratory system Common – cough.
Dermatological reactions Common – rash.
Allergic reactions Uncommon – hypersensitivity reactions (erythematous rash, generalized rash, erythema, eyelid edema, facial edema, peripheral edema, facial swelling, pruritus, generalized pruritus, dyspnea); Unknown – urticaria, angioedema.
Other Unknown – fever, fatigue.
Contraindications
Hypersensitivity to the components of the drug used, pregnancy, breastfeeding period.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and breastfeeding.
Pediatric Use
Used in children in the appropriate dosage form.
Special Precautions
In case of respiratory disorders or other symptoms of drug intolerance, treatment should be discontinued, as these symptoms are manifestations of an allergic reaction.
Drug Interactions
Can be used concomitantly with other drugs for the therapy of acute and chronic respiratory diseases.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Capsules 7 mg: 10 or 30 pcs.
Marketing Authorization Holder
OM Pharma, S.A. (Switzerland)
Dosage Form
| Broncho-Vaxom® adult | Capsules 7 mg: 10 or 30 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size No. 3, opaque blue cap and body; capsule contents are a light beige powder.
| 1 cap. | |
| Standardized lyophilisate of bacterial lysates | |
| Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis | 7 mg |
Excipients : propyl gallate anhydrous (E310) – 0.084 mg, sodium glutamate – 3.03 mg, mannitol – up to 40 mg, pregelatinized starch – 110 mg, magnesium stearate – 3 mg, mannitol – up to 200 mg.
Capsule shell composition indigotine (indigo carmine) dye (E132) – 0.03 mg, titanium dioxide (E171) – 1 mg, gelatin – up to 50 mg.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
Capsules 3.5 mg: 10 or 30 pcs.
Marketing Authorization Holder
OM Pharma, S.A. (Switzerland)
Dosage Form
| Broncho-Vaxom® children | Capsules 3.5 mg: 10 or 30 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size No. 3, opaque blue cap, opaque white body; capsule contents are a light beige powder.
| 1 cap. | |
| Standardized lyophilisate of bacterial lysates | |
| Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis | 3.5 mg |
Excipients : propyl gallate anhydrous (E310) – 0.042 mg, sodium glutamate – 1.515 mg, mannitol – up to 20 mg, pregelatinized starch – 110 mg, magnesium stearate – 3 mg, mannitol – up to 200 mg.
Capsule shell composition indigotine (indigo carmine) dye (E132) – 0.01 mg, titanium dioxide (E171) – 1 mg, gelatin – up to 50 mg.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
